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AIM:  To  investigate  whether  blood  serotonin
(5-hydroxytryptamine)  (5-HT)  modulates  musculos-
keletal pain differently in seropositive and seronega-
tive rheumatoid arthritis (RA).
Methods:  Patients  with  temporomandibular  joint
(TMJ) involvement of seropositive RA (33 patients) or
seronegative RA (28 patients) and 26 healthy individ-
uals were included. TMJ pain, general musculoskele-
tal pain, plasma and serum 5-HT, acute phase reac-
tants and thrombocyte count were investigated.
Results: The patients with seropositive RA had higher
serum (median = 1130nmol/l) and plasma (55nmol/
l)  levels  of  5-HT  than  the  healthy  individuals
(704nmol/l,  p =  0.044  and  23nmol/l,  p <  0.001,
respectively), and higher plasma levels of 5-HT than
the seronegative patients (14nmol/l, p < 0.001). There
was  no  significant  correlation  between  serum  and
plasma levels of 5-HT in any group.
In  the  seropositive  RA  patients,  positive  correla-
tions were found between serum levels of 5-HT and
the number of painful mandibular movements (rs =
0.36, n = 33, p = 0.042), as well as pain on maximum
mouth  opening  (rs =  0.41,  n =  24,  p =  0.047)  and
tenderness to digital palpation (rs = 0.49, n = 33, p =
0.003).
In  the  healthy  individuals,  there  was  a  negative
correlation between plasma level of 5-HT and the TMJ
pressure  pain  threshold  (rs =  –0.47,  n =  20,  p =
0.037).
Conclusion:  Peripheral  serotonergic  pain  mecha-
nisms seem to be activated by blood 5-HT in patients
with  seropositive  RA,  in  contrast  to  seronegative
patients.
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Introduction
Serotonin  (5-hydroxytryptamine)  (5-HT)  has  been
shown peripherally to induce plasma extravasation,1,2
to modulate vasotonus,3–6 and to sensitize or excite
nociceptors.7–11 Furthermore,  5-HT  participates  in
the  peripheral  modulation  of  musculoskeletal  pain
associated with rheumatoid arthritis (RA).12–16
5-HT is produced by enterochromaffin cells in the
gastrointestinal mucosa and most of it is immediately
absorbed to and stored in the circulating  thrombo-
cytes.17The total blood content of 5-HT thus consists
of the 5-HT stored in the thrombocytes as well as an
unbound plasma fraction, which comprises approx-
imately 5–15% of the total blood concentration.14,18
Thrombocytes from patients with rheumatic diseases
have been found  to have a lower number  of  intra-
cellular  5-HT  storage  organelles  compared  with
thrombocytes  from  healthy  individuals,  indicating
that the thrombocytes have been activated to release
5-HT. Accordingly, the thrombocyte content of 5-HT is
decreased  during  acute  episodes  of  RA.15 Platelet-
activating factors such as immune complexes, includ-
ing the rheumatoid factor, activate thrombocytes to
release 5-HT.16,19 Presence of the rheumatoid factor in
the blood from patients with RA has been associated
with high inflammatory activity and poor prognosis
with  respect  to  temporomandibular  joint  (TMJ)
involvement20, which might partly be explained by
thrombocyte activation.
The  aim  of  the  present  study  was  therefore  to
investigate  whether  musculoskeletal  pain  including
TMJ pain is modulated by serum or plasma 5-HT in
patients with RA, and whether there is a difference in
this aspect between the seropositive and seronegative
forms of the disease.
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Patients
This study comprised 13 male and 48 female patients
with  seropositive (33  patients)  or  seronegative (28
patients) RA, and was approved by the local Ethical
Committee at Huddinge University Hospital (460/99).
The  examinations  and  blood  samplings  were  con-
ducted with  the understanding and  the consent of
each  subject. The  distribution  of  gender,  age  and
duration  of  general  as  well  as  temporomandibular
symptoms is presented in Table 1. The patients were
referred to the Department of Clinical Oral Physiology
from medical practitioners due to TMJ involvement of
RA. The inclusion criteria for this study were diagnosis
of RA according to the 1987 diagnostic criteria by the
American College of Rheumatology,21 as well as TMJ
arthritis according to the diagnostic classification by
the  American  Academy  of  Orofacial  Pain.22 The
patients had not been subjected to any recent (< 3
month) specific treatment of  local pain in the TMJ.
Patients whose symptoms could be referred to disease
in  other  components  of  the  temporomandibular
system (e.g. toothache, myalgia or neuralgia), or local
infection of the skin over the TMJ were excluded.
Regarding  ongoing  medication,  12  of  the  ser-
opositive  patients  and  four  of  the  seronegative
patients used glucocorticoids, 17 of the seropositive
patients  and  five  of  the  seronegative patients  used
disease-modifying anti-rheumatic drugs, and 21 of the
seropositive  patients  and  10  of  the  seronegative
patients used non-steriodal anti-inflammatory drugs.
Of the seropositive patients, six patients did not use
any medication, and the corresponding figure for the
seronegative  patients  was  15  patients.  More  ser-
opositive  patients  used  disease-modifying  anti-rheu-
matic drugs than the seropositive patients (p = 0.014),
while less seropositive patients used no medication
compared  with  the  seronegative  patients  (p =
0.009).
The patients  were divided into  two  groups  with
respect to  presence  (seropositive)  or  absence (ser-
onegative) of rheumatoid factor in serum.
Healthy individuals
For comparison, a group of 10 male and 16 female
healthy individuals was included in the study (Table
1).  The  healthy  individuals  had  no  history  of  or
clinical signs of ongoing temporomandibular disorder
or pain.
The  conduct of  this  study  was  approved  by  the
ethical  committee  at  Huddinge  University  Hospital
(310/97).
Blood sampling
Venous blood was collected from  the patients in  a
sodium citrate tube (0.105mol/l) for measurement of
the erythrocyte sedimentation rate and the thrombo-
cyte  particle  concentration  in  the  blood.  Another
sample  was  obtained  in  an  ethylenediamine  tetra-
acetic  acid  tube  that  was  immediately  cooled  and
centrifugated (1500 ´ g for 30min at 4°C). The upper
third  of  the  supernatant  (i.e.  platelet-poor  plasma)
was obtained, frozen (–70°C) and later examined for
the  platelet-poor plasma  level  of  5-HT.  In  addition,
venous  blood  was  collected  without  additives  for
analysis of the serum level of 5-HT, rheumatoid factor
and C-reactive protein. These tubes were left at room
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Table 1. Gender, age, duration of general and TMJ symptoms as well as number of painful
musculoskeletal regions in 33 patients with seropositive RA and 28 patients with seronegative
RA involving the TMJ, as well as in 26 healthy individuals
Group Median IQR n
Seropositive RA patients 33
Gender (males/females) 8/25
Age (years) 52 12
Duration
General (years) 12 10
TMJ (years) 5 5
Seronegative RA patients 28
Gender (males/females) 5/23
Age (years) 44 14
Duration
General (years) 12 11
TMJ (years) 4 5
Healthy individuals 26
Gender (males/females) 10/16
Age (years) 38 11
IQR, Interquartile range; n, number of observations.temperature  for  60min  to coagulate and  thereafter
centrifuged  (1500  ´ g for  10min  at  +4°C).  The
rheumatoid factor concentration was analyzed with
the routine procedure (nephalometry) at the depart-
ment  of  Clinical  Immunology,  Huddinge  University
Hospital  and  measured  in  international  units  per
millilitre  (IU/ml).  C-reactive  protein  was  analyzed
with Tina-quant® CRP, an immunoturbidimetric assay;
precision  of  the  assay:  intra-assay  and  inter-assay
coefficient of variation < 7%, and the detection limit
3mg/l (Roche, Basel, Switzerland). C-reactive protein
values below 10mg/l and concentrations of rheuma-
toid factor below 15IU/ml were considered as zero
values. The remaining serum was then frozen (–20°C)
until analysis of 5-HT. Blood samples from the healthy
individuals were  obtained as  already described and
analyzed for plasma and serum levels of 5-HT as well
as thrombocyte particle concentration.
Assessment of subjective symptoms and
clinical signs
The patients were asked about current pain in nine
joint regions besides the TMJ region (neck, shoulders,
elbows, hands, upper back, lower back, hips, knees
and  feet)  and  the  number  of  painful  regions  was
recorded (score =  0–9). A  100mm  visual  analogue
scale  (VAS)  (ACO,  Stockholm,  Sweden)  with  end-
points  marked with ‘No pain’  (score  0)  and ‘Worst
pain ever experienced’ (score = 0–100) was used to
assess the current resting pain intensity experienced
in the TMJ region and the joint pain in general. A score
of  tenderness  to  digital  palpation  of  the TMJ  was
adopted that comprised tenderness of the lateral and
posterior  aspect  of  the  joint.  On  each  side  and
location (lateral and posterior), one unit was scored if
the patient reported tenderness and two units if the
palpation caused a pain reflex (score per joint = 0–4).
The  pressure  pain  threshold  to  linearly  increasing
pressure over the lateral aspect of the TMJ as well as
over a reference site, glabella on the frontal bone, was
assessed with an electronic algometer (Somedic Sales
AB, Sollentuna, Sweden) with a 1cm2 blunt rubber tip
and  a  pressure  rate  of  50kPa/s.  The  number  of
different mandibular movements provoking TMJ pain,
including maximum mouth opening, laterotrusion to
both sides and protrusion, was counted on each side
(score = 0–4). Pain on maximum mouth opening was
also recorded on a 100-mm VAS.
Blood 5-HT and joint pain in RA
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Table 2. Median, interquartile range (IQR), number of observations (n) and percent observations exceeding 0 (% positive)
regarding clinical and blood variables in 33 patients with seropositive RA, 28 patients with seronegative RA and 26 healthy
individuals
Variable Patients
Seropositive RA
Median IQR n % positive
Seronegative RA
Median IQR n % positive
Healthy individuals
Median IQR n % positive
Number of painful joint
regions (0–9)
5 4 33 100 3 3 28 96 0 0 26 0
General joint pain intensity
(VAS)
60 36 23 96 37 31 23 91 0 0 26 0
Pressure pain threshold,
reference site (kPa)
267 181 18 100 224 125 22 100 313 120 19 100
Serum level of serotonin
(nmol/l)
1130 692 33 100 919 799 28 100 704 519 26 100
Plasma level of serotonin
(nmol/l)
55 41 21 100 14 20 22 100 23 19 20 100
Erythrocyte sedimentation rate
(mm/h)
32 25 29 100 14 18 27 100 n.a.
C-reactive protein (mg/l) 11 24 30 60 0 6 27 41 0 0 15 5
Thrombocyte particle count (´
10
9/l)
350 73 26 100 292 70 26 100 266 60 15 100
Rheumatoid factor (IU) 48 154 31 77 0 0 27 0 n.a.
TMJ pain intensity (VAS) 50 52 33 85 68 29 26 100 0 0 26 4
Pressure pain threshold of the
TMJ (kPa)
324 113 33 100 324 152 26 100 414 146 20 100
Tenderness to digital palpation
of the TMJ (0–8)
2 2 33 97 2 2 28 89 0 0 26 12
Pain intensity on maximum
mouth opening (VAS)
51 68 24 75 71 31 23 96 0 0 24 13
Number of painful mandibular
movements (0–4)
3 2 33 88 5 2 28 96 0 0 26 19
n.a., Not applicable.Analysis of serotonin
Serotonin was  analyzed  in  duplicate  by  a  commer-
cially  available  enzyme  immunoassay  kit  (Nr  0642;
Immunotech  International, Germany)  with  a  detec-
tion limit and sensitivity of 0.5nmol/l. The intra-assay
coefficient  of  variation  is  reported  by  the  manu-
facturer  to  be  less  than  9.4%,  and  the  inter-assay
coefficient  of  variation  less  than  9.9%. The  serum
5-HT samples were diluted 1:20 prior to analysis and
the values obtained were corrected for the dilution.
Statistics
When joint-related variables were correlated to vari-
ables related to the individual, the sum of the left and
right side was used. Non-parametric statistical meth-
ods  were  used  including  median  and  interquartile
range (75th percentile-25th percentile) for descriptive
statistics. The significance of differences in distribu-
tion  of  medication  between  the  seropositive  and
seronegative patients was tested with the x
2-test. The
significance  of  the  differences  between  the  three
groups  was  tested  with  the  one-way  analysis  of
variance on ranks with Dunn’s multiple comparison
post-hoc test. Spearman’s ranked correlation test was
used  to  test  the  significance  of  the  correlations. A
probability  level  of  p <  0.05  was  considered
significant.
Results
Table 2 presents the clinical and blood variables for
the  patient  groups  as  well  as  for  the  healthy
individuals.
Serotonin concentrations
The patients with seropositive RA had higher serum
and plasma levels of 5-HT than the healthy individuals
(p = 0.044  and p < 0.001, respectively; Fig. 1) and
higher plasma levels  of  5-HT  than the seronegative
patients  (p <  0.001;  Fig.  1)  when  all  groups  were
compared. The highest plasma and serum levels were
found in the patients with seropositive RA: 218 and
3530nmol/l, respectively.
There  was  no  significant  correlation  between
serum  and  plasma  levels  of  5-HT  in  any  group.  In
addition,  there  were  no  differences  in  serum  or
plasma  levels  of  5-HT  between  patients  that  used
medication  with  glucocorticoid,  disease-modifying
anti-rheumatic drugs or non-steriodal anti-inflamma-
tory drugs and those patients who did not use these
medications.
Serotonin and pain
In the seropositive RA patients, positive correlations
were found  between serum  levels  of  5-HT  and the
number of painful mandibular movements (rs = 0.36,
n =  33,  p =  0.042),  as  well  as  pain  on  maximum
mouth opening (rs = 0.41, n = 24, p = 0.047; Fig. 2)
and tenderness to digital palpation (rs = 0.49, n = 33,
p = 0.003).
In  the  healthy  individuals,  there  was  a  negative
correlation between the plasma level of 5-HT and the
TMJ  pressure  pain  threshold  (rs =  –0.47,  n =  20,
p = 0.037; Fig. 3).
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FIG. 1. Box plot showing serum and plasma levels of 5-HT in 33 patients with seropositive rheumatoid arthritis (RA/RF+), 28
patients with seronegative RA (RA/RF–) and 26 healthy individuals. The seropositive patients had higher serum and plasma
levels of 5-HT than the healthy individuals (p = 0.044 and p < 0.001, respectively).Group differences
The seropositive RA patients had a higher number of
joint regions involved with the disease (p =  0.004)
and a higher degree of general joint pain (p = 0.006)
compared  with  the  seronegative  patients.  On  the
contrary, the seronegative patients showed a higher
degree  of TMJ  resting  pain  (p =  0.049),  pain  on
maximum mouth opening (p = 0.015) and a higher
number of painful TMJ movements (p < 0.001) than
the  seropositive  patients. The  seropositive  patients
had a significantly higher erythrocyte sedimentation
rate  (p <  0.001),  thrombocyte  particle  count  (p =
0.009)  and C-reactive protein (p <  0.001)  than the
seronegative patients.
There was  a  positive  correlation between  serum
level of 5-HT and thrombocyte particle count in the
seropositive  (rs =  0.42,  n =  26,  p =  0.031)  and
seronegative patients (rs = 0.48, n = 26, p = 0.013).
When all three groups were compared, the patients
with seronegative RA had lower TMJ and reference
site pressure pain thresholds than the healthy individ-
uals (p = 0.020 and p = 0.039, respectively).
Discussion
The present study shows that high serum concentra-
tion of 5-HT is associated with TMJ pain and palpatory
tenderness  in  patients  with  TMJ  arthritis  due  to
seropositive RA. These patients had elevated serum
and  plasma  concentrations  of  5-HT  and  a  higher
inflammatory  activity  than  the  patients  with  ser-
onegative RA.
Regarding the patients with seropositive RA, these
findings  are  in  agreement  with  a  previous  study
where a high serum level of 5-HT was found to be
associated with pain during mandibular movements
in RA patients.23 However, this relationship seems to
be  confined  to  seropositive  RA,  according  to  the
results  in  the  present  study. The  high  total  blood
content  of  5-HT  in  this  group  seems  to  influence
nociception  within  the TMJ,  suggesting  that  serum
5-HT is involved in the modulation of inflammation
and joint pain in seropositive patients.
Thrombocytes are supposed to be the major source
of  5-HT  in  the  blood. A high  thrombocyte particle
count was associated with high serum level of 5-HT in
both groups of patients, supporting this condition in
Blood 5-HT and joint pain in RA
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FIG. 2. Scatter plot showing the relation between the serum level of 5-HT and TMJ pain intensity, as assessed with a VAS
(0–100mm), experienced on maximum mouth opening in patients with (A) seropositive RA (rs = 0.41, n = 24, p = 0.047) and (B)
seronegative RA (rs = –0.27, n = 23, p = 0.214)
FIG. 3. The relation between the plasma level of 5-HT and the
sum of pressure pain thresholds over the lateral aspects of
the right and left temporomandibular joints  in 20 healthy
individuals (rs = –0.47, n = 20, p = 0.037).RA  patients.  In  the  seropositive patients,  thrombo-
cytes  were  present  in  higher  numbers  than  in  the
seronegative  patients.  The  thrombocyte  count  is
increased during periods of  high  general inflamma-
tory activity, although it was not significantly corre-
lated  with  erythrocyte  sedimentation  rate  or
C-reactive  protein  in  this  study.  However,  the  ser-
opositive patients  had higher  general  inflammatory
activity, according to the erythrocyte sedimentation
rate and C-reactive protein level as well as the more
pronounced  general  clinical  signs,  than  the  ser-
onegative  patients,  which  thus  may  explain  the
higher serum 5-HT level in these patients.
The  thrombocytes  may  become  activated during
inflammation by platelet-activating factors such as the
rheumatoid factor  to release 5-HT,  which  increases
plasma  and  thereby  also  tissue  5-HT  levels.12,15
Presence of  the  rheumatoid factor  in  the  blood  of
patients with RA has been found to be associated with
poor  prognosis  and  higher  disease  activity  with
respect to the TMJ,20 and patients with seropositive
RA  generally  present  more  pronounced TMJ  symp-
toms,24,25 which  was  also  the  fact  in  the  present
study. The lack of significant correlation between the
plasma  level  of  5-HT  and  the thrombocyte particle
count  in  our  study  indicates  that other  sources  of
5-HT (e.g. mast cells) contribute to the plasma level or
that  there  is  a  large  variation  in  the  degree  of
thrombocyte activation in these patients. The varia-
tion  in  titer  of  the  platelet-activating  rheumatoid
factor16,19 in the seropositive patients may explain the
latter condition. Nevertheless, our findings show that
the  plasma  level  of  5-HT  is  abnormally  high  in
seropositive  patients  but  not  in  seronegative
patients.
An increased plasma level of 5-HT would probably
cause an immediate increase of the tissue 5-HT level,
resulting in enhanced stimulation of peripheral 5-HT
receptors. In turn, this may sensitize nociceptors and
cause  pain,  hyperalgesia  or  allodynia.7,8,10 The  ser-
opositive group showed elevated serum and plasma
levels  of  5-HT  as  well  as  elevated  general  disease
activity.  5-HT  may  therefore  be  one  factor  in  the
modulation  of  general  hyperalgesia/allodynia  in
patients  with  seropositive  RA,  although  no  direct
association between  5-HT  levels  and  pressure  pain
threshold over  the reference site was found  in  the
present study.
The  present  study  shows  differences  between
patients with seropositive and seronegative RA con-
cerning  inflammatory  activity  and  contribution  of
serotonergic  mechanism  to  TMJ  pain.  Peripheral
serotonergic  pain  mechanisms  do  not  seem  to  be
important in  the seronegative patients, while these
mechanisms  seem  to  influence  pain  in  the  ser-
opositive patients. As previously discussed, one rea-
son  for  this  difference  can  be  a  higher  degree  of
thrombocyte activation in the seropositive patients.
Another  explanation  could  be  differences  in  5-HT
receptor  expression  on  nociceptors  and  blood
vessels.
The association between high plasma level of 5-HT
and low pressure pain threshold over the TMJ in the
healthy  individuals  is  remarkable,  since it indicates
that unbound 5-HT in the blood is able to sensitize
peripheral  nociceptors  for  mechanical  stimulation.
This is in concordance with a previous study where
high plasma 5-HT was associated with low pressure
pain threshold over the masseter muscle.14 In addi-
tion, injection of 5-HT into the masseter muscle of
healthy individuals causes more local pain and a larger
decrease in local pressure pain thresholds than does
injection of saline.26 5-HT may thus be one determi-
nant  of  TMJ  pressure  pain  threshold  in  healthy
individuals,  which  strengthens  the  assumption  that
the plasma level of 5-HT has a role in physiological
nociception. The  difference  between  patients  and
healthy individuals with respect to this relation could
be due to a difference in the 5-HT receptor population
on the nociceptors.17
In  conclusion,  the  present  study  indicates  that
peripheral  serotonergic  pain  mechanisms  are  acti-
vated by blood 5-HT in patients with seropositive RA,
in contrast to seronegative RA patients.
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